Sign in
Taking peoplePhase 4

Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection

Key facts

Who runs it
Shanghai Zhongshan Hospital
Where
China7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
236 people, planned
Started
29 Sept 2025
Expected to end
30 Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Conventional treatment
  • Sivelestat sodium
  • Placebo
Record updated
10 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18-75 years inclusive
  • Written informed consent obtained before participation
  • Confirmed acute Stanford type A aortic dissection scheduled for surgical repair

Who cannot take part

  • Severe pre-operative renal dysfunction: acute or chronic kidney injury meeting criteria for renal-replacement therapy
  • Immunosuppression: long-term or > 2 weeks continuous systemic corticosteroids
  • Concomitant or anticipated use of immunomodulators (Xue-Bi-Jing injection, thymosin, IVIG)
  • Medical or psychological condition that would interfere with study participation, assessment, or outcomes
  • Life expectancy ≤ 48 hours
  • Pregnant or lactation
  • Severe pre-operative liver dysfunction: Child-Turcotte-Pugh score 10-15
  • Confirmed COPD or asthma

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:

Read full original descriptionShow less

* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)? * Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5? * Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.

Participants will:

* Take drug Siv or the placebo through vein continuously for 72 hours * Receiving regular intensive care in ICU after the operation

The 2 groups in the trial

  • Sivelestat groupTreatment being tested

    Drug: Sivelestat Sodium. Procedure: Conventional Treatment

    Treatment: Conventional treatment and Sivelestat sodium

  • Control groupPlacebo, for comparison

    Drug: Placebo. Procedure: Conventional Treatment

    Treatment: Conventional treatment and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of the Efficacy of Sivelestat Sodium Treatment in Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection (STOP): a Multicenter, Double-blind RCT
Criteria questions
Built from NCT07156656, who can take part
Record updated
10 November 2026